Treatment of affective disorders in cardiac disease

Dialogues in Clinical Neuroscience

Volumn 17, Issue 2, 2015, Pages 127-140

  Mavrides, Nicole ^a   Nemeroff, Charles B ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Antidepressant; Anxiety; Cardiac disease; Cardiovascular disease; Coronary artery syndrome; Depression; Post MI; SSRI; Treatment of depression or anxiety

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; CITALOPRAM; DULOXETINE; ESCITALOPRAM; FLUOXETINE; IMIPRAMINE; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; NORTRIPTYLINE; PAROXETINE; PLACEBO; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE; VILAZODONE;

ANXIETY; ARTICLE; BRADYCARDIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; DEPRESSION; DRUG EFFICACY; DRUG SAFETY; ELECTROCONVULSIVE THERAPY; ELEVATED BLOOD PRESSURE; HEART BLOCK; HEART DISEASE; HEART FAILURE; HEART INFARCTION; HEART MUSCLE CONDUCTION DISTURBANCE; HEART RATE VARIABILITY; HUMAN; HYPERTENSION; INFLAMMATION; LIFESTYLE; MAJOR DEPRESSION; MOOD DISORDER; MULTICENTER STUDY (TOPIC); ORTHOSTATIC HYPOTENSION; PATHOPHYSIOLOGY; PREVALENCE; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; TACHYCARDIA; THROMBOCYTE FUNCTION; TRANSCRANIAL MAGNETIC STIMULATION; VAGUS NERVE STIMULATION; COMPLICATION; HEART DISEASES; HEART RATE; MOOD DISORDERS; PHYSIOLOGY; PROCEDURES; RISK FACTOR;

ANTIDEPRESSIVE AGENTS; HEART DISEASES; HEART RATE; HUMANS; INFLAMMATION; LIFE STYLE; MOOD DISORDERS; PSYCHOTHERAPY; RISK FACTORS;

EID: 84940785827     PISSN: 12948322     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (80)

1. Halaris A. Comorbidity between depression and cardiovascular disease. Int Angiol. 2009;28:92-99.
2. Dowlati Y, Herrmann N, Swardfager WL, Reim EK, Lanctot KL. Efficacy and tolerability of antidepressants for treatment of depression in coronary artery disease: A meta-analysis. Can J Psychiatry. 2010;55(2):91-99.
3. Celano CM, Huffman JC. Depression and cardiac disease. A review. Cardiol Rev. 2011;19(3):130-142.
4. Maltzberg B. Mortality among patients with involution melancholia. Am J Psychiatry. 1937;93:1231-1238.
5. Nemeroff CB, Goldschmidt-Clermont PJ. Heartache and heartbreak - the link between depression and cardiovascular disease. Nat Rev Cardiol. 2012;9(9):1-14.
6. Garfield LD, Scherrer JF, Hauptman PJ, et al. Association of anxiety disorders and depression with incident heart failure. Psychosom Med. 2014;76:128-136.
7. Bucknall C, Brooks D, Curry PV, Bridges PK, Bouras N, Ankier SI. Mianserin and trazodone for cardiac patients with depression. Eur J Clin Pharmacol. 1988;33(6):565-569.
8. Scherrer JF, Chrusciel T, Garfield LD, et al. Treatment-resistant and insufficiently treated depression and all-cause mortality following myocardial infarction. Br J Psychiatry. 2012;200:137-142.
9. Sowden GL, Huffman JC. The impact of mental illness on cardiac outcomes: A review for the cardiologist. Int J Cardiol. 2009;132:30-37.
10. Scherrer JF, Garfield LD, Lustman PJ, et al. Antidepressant drug compliance: reduced risk of MI and mortality in depressed patients. Am J Med. 2011;124:318-324.
11. Ramasubbu R, Beaulieu S, Taylor VH, Schaffer A, McIntylre RS. The CANMAT task force recommendations for the management of patients with mood disorders and comorbid medical conditions: Diagnostic, assessment, and treatment principles. Ann Clin Psychiatry. 2012;24(1):82-90.
12. Taylor D, Meader N, Bird V, Pilling S, Creed F, Goldberg D. Pharmacological interventions for people with depression and chronic physical health problems: Systematic review and meta-analysis of safety and efficacy. Br J Psychiatry. 2011;198:179-188.
13. Van Melle JP, de Jonge P, Honig A, et al. Effects of antidepressant treatment following myocardial infarction. Br J Psychiatry. 2007;190:460-466.
14. Lesperance F, Frasure-Smith N, Koszycki D, et al. Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease. The Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy (CREATE) Trial. JAMA. 2007;297:367-379.
15. Alvarez W, Pickworth KK. Safety of antidepressant drugs in the patient with cardiac disease: A review of the literature. Pharmacotherapy. 2003;23(6):754-771.
16. McIntyre RS, Schaffer A, Beaulieu S. The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid conditions. Ann Clin Psychiatry. 2012;24(1):1-3.
17. Cowles MK, Musselman DL, McDonald W, Nemeroff CB. Effects of mood and anxiety disorders on the cardiovascular system. In: Hurt's the Heart. 13th ed: two volume set. New York, NY: McGraw-Hill Publishers; 2010;Chapter 96:2128-2145
18. Holt RIG, Phillips DIW, Jameson KA, Cooper C, Dennison E, Peveler RC. The relationship between depression, anxiety, and cardiovascular disease: Findings from the Hertfordshire Cohort Study. J Affect Disord. 2013;150:84-90.
19. Iosifescu DV, Clementi-Craven N, Fraguas R, et al. Cardiovascular risk factors may moderate pharmacological treatment effects in major depressive disorder. Psychosom Med. 2005;67:703-706.
20. Smoller JW, Allison M, Cochrane BB, et al. Antidepressant use and risk of incident cardiovascular morbidity and mortality among postmenopausal women in the women's health initiative study. Arch Intern Med. 2009;169(22):2128-2139.
21. Taylor CB, Conrad A, Wilhelm FH, et al. Does improving mood in depressed patients alter factors that may affect cardiovascular disease risk? J Psychiatr Res. 2009;43:1246-1252.
22. Windle M, Windle RC. Recurrent depression, cardiovascular disease, and diabetes among middle-aged and older adult women. J Affect Disord. 2013;150:895-902.
23. Frasure-Smith N, Lesperance F., Talajic M. Depression following myocardial infarction. Impact on 6 month survival. JAMA. 1993;270:1819-1825.
24. Chiaie RD, Capra E, Salviati M, et al. Persistence of subsyndromal residual symptoms after remission of major depression in patients without cardiovascular disease may condition maintenance of elevated platelet factor 4 and ß-thromboglobulin plasma levels. J Affect Disord. 2013;150:664-667.
25. Paslakis G, Kopf D, Westphal S, et al. Treatment with paroxetine, but not amitriptyline, lowers levels of lipoprotein(a) in patients with major depression. J Psychopharmacol. 2011;25(10):1344-1346.
26. Pozuelo L, Zhang J, Franco K, Tesar G, Penn M, Jiang W. Depression and heart disease: What do we know, and where are we headed? Cleve Clin J Med. 2009;76(1):59-70.
27. Lopez-Vilchez I, Serra-Millas M, Navarro V, et al. Prothrombotic platelet phenotype in major depression: Downregulation by antidepressant treatment. J Affect Disord. 2014;159:39-45.
28. Wium-Andersen MK, Orsted DD, Nordestgaard BG. Elevated plasma fibrinogen, psychological distress, antidepressant use, and hospitalization with depression: Two large population-based studies. Psychoneuroendocrinology. 2013;38:638-647.
29. Blumenthal JA, Sherwood A, Babyak MA, et al. Exercise and pharmacological treatment of depressive symptoms in patients with coronary heart disease: results from the UPBEAT (Understanding the Prognostic Benefits of Exercise and Antidepressant Therapy) study. J Am Coll Cardiol. 2012;60:1053-1063.
30. Ruo B, Rumsfeld JS, Hlatky MA, Liu H, Browner WS, Whooley MA. Depressive symptoms and health related quality of life: the Heart and Soul Study. JAMA. 2003;290:215-221.
31. Hamer M, Batty GD, Seldenrijk A, Kivimaki M. Antidepressant medication use and future risk of cardiovascular disease: the Scottish Health Study. Eur Heart J. 2010;32(4):437-42.
32. Kemp AH, Brunoni AR, Santos IS, et al. Effects of depression, anxiety, comorbidity, and antidepressants on resting-state heart rate and its variability An ELSA-Brasil cohort baseline study. Am J Psychiatry. 2014;171(2):1328-1334.
33. Gehi A, Haas D, Pipkin S, Whooley MA. Depression and medication adherence in outpatients with coronary heart disease: findings from the Heart and Soul Study. Arch Intern Med. 2005;165(21):2508-2513.
34. Su S, Lampert R, Lee F, et al. Common genes contribute to depressive symptoms and heart rate variability: The Twins Heart Study. Twin Res Hum Genet. 2010;13(1):1-9.
35. Su S, Miller AH, Sneider H, et al. Common genetic contributions to depressive symptoms and inflammatory markers in middle-aged men: The Twins Heart Study. Psychosom Med. 2009;71:152-158.
36. Rubin RR, Peyrot M, Gaussoin SA., et al. Four-year analysis of cardiovascular disease risk factors, depression symptoms, and antidepressant medicine use in the Look AHEAD (Action for Health in Diabetes) clinical trial of weight loss in diabetes. Diabetes Care. 2013;36:1088-1094.
37. Mannie ZN, Williams C, Diesch J, Steptoe A, Leeson P. Cardiovascular and metabolic risk profile in young people at familial risk of depression. Br J Psychiatry. 2013;203(1):18-23.
38. Blumenthal JA. New frontiers in cardiovascular behavioral medicine: Comparative effectiveness of exercise and medication in treating depression. Cleve Clin J Med. 2011;78:S35-S43.
39. Baumeister H, Hutter N, Bengel K. Psychological and pharmacological interventions for depression in patients with coronary artery disease. Cochrane Database Syst Rev. 2011;9:CD008012.
40. Hoenr PW, Denollet J, de Jonge P, Whooley MA. Positive affect and survival in patients with stable coronary heart disease: Findings from the Heart and Soul Study. J Clin Psychiatry. 2013;74(7):716-722.
41. Van den Brink RHS, Van Melle JP, Honig A, et al. Treatment of depression after myocardial infarction and the effects on cardiac prognosis and quality of life: Rationale and outline of the Myocardial Infarction and Depression-Intervention Trial. Am Heart J. 2002;144(2):219-225.
42. Santangelo A, Testai M, Barbagallo P, et al. Use of specific serotonin reuptake inhibitors (SSRIs) (sertraline or citalopram) in the treatment of depression reduces the cardiovascular risk in the elderly. Evidence from a Sicilian population >80 years recovered in the assisted sanitary residences (RSA). Arch Gerontol Geriatr. 2009;48:350-352.
43. Cohen JB, Wilcox CS, Goodman L. Antidepressant efficacy and safety of trimipramine in patients with mild heart disease. Clin Ther. 1993;15:114-126.
44. Nelson JC, Kennedy JS, Pollock BG, et al. Treatment of major depression with nortriptyline and paroxetine in patients with ischemic heart disease. Am J Psychiatry. 1999;156(7);1024-1028.
45. Roose SP, Glassman AH. Antidepressant choice in the patient with cardiac disease: lessons from the cardiac arrhythmias suppression trials (CAST) studies. J Clin Psychiatry. 1994;55(suppl A):83-87.
46. Roose SP, Glassman AH, Giardina EV, Johnson LL, Resovsky K, Le Winter M. Cardiovascular effects of imipramine and bupropion in depressed patients with congestive heart failure. J Clin Psychopharmacol. 1987;7:247-251.
47. Roose SP, Laghrissi-Thode F, Kennedy JS, et al. Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease. JAMA. 1998;279(4):287-291.
48. Yeragani VK, Roose S, Mallavarapu M, Radhakrishna RK, Pesce V. Major depression with ischemic heart disease: effects of paroxetine and nortriptyline on measures of nonlinearity and chaos of heart rate. Neuropsychobiology. 2002;46(3):125-135.
49. Roose SP, Glassman AH, Attia E, Woodring S, Giardina EV, Bigger JT. Cardiovascular effects of fluoxetine in depressed patients with heart disease. Am J Psychiatry. 1998;155:660-665.
50. Strik JJ, Honig A, Lousberg R. Efficacy and safety of fluoxetine in the treatment of patients with major depression after first myocardial infarction: findings from a double-blind placebo-controlled trial. Psychosom Med. 2000;62:783-789.
51. Shapiro PA, Lesperance F, Frasure-Smith N. An open-label preliminary trial of sertraline for treatment of major depression after acute myocardial infarction (SAHDAT trial). Sertraline Anti-Depressant Heart Attack Trial. Am Heart J. 1999;37:1100-1106.
52. Glassman AH, O'Connor CM, Califf RM etal. Sertraline Antidepressant Heart Attack Randomized Trial (SADHART) Group. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA. 2002;288(6):401-709.
53. Glassman AH, Bigger, JT. Depression and cardiovascular disease: The safety of antidepressant drugs and their ability to improve mood and reduce medical morbidity. In: Depression and Heart Disease. New York, NY: Wiley and Sons; 2011; Chapter 5.
54. O'Connor CM, Jiang W, Kuchibhatla M, et al. Safety and efficacy of sertraline for depression in patients with heart failure. Results of the SAD-HART-CHF (Sertraline Against Depression and Heart Disease in Chronic Heart Failure) Trial. J Am Coll Cardiol. 2010;56(9):692-699.
55. O'Connor CM, Jiang W, Kuchibhatla M, et al. Antidepressant use, depression, survival in patients with heart failure. Arch Int Med. 2008;168(2):2232-2237.
56. Habra ME, Baker B, Frasure-Smith N, et al. First episode of major depressive disorder and vascular factors in coronary artery disease. Baseline characteristics and response to antidepressant treatment in the CREATE trial. J Psychosom Res. 2010;69(2):133-141.
57. Bekke-Hansern S, Trockel M, Burg MM, Taylor CB. Depressive symptom dimensions and cardiac prognosis following myocardial infarction: results from the ENRICHD clinical trial. Psychol Med. 2012;42:51-60.
58. Enriched Investigators: Carney RM. et al. Enhancing recovery in coronary heart disease (ENRICHD) study interventions: Rationale and design. Psychosom Med. 2001;63:747-755.
59. Honig A, Kuyper AM, Schene AH, et al. Treatment of post-myocardial infacrtion depressive disorder: a randomized, placebo-controlled trial with mirtazapine. Psychosom Med. 2007;69:606-613.
60. Weeke P, Jensen A, Folke F, et al. Antidepressant use and risk of outof-hospital cardiac arrest: A nationwide case-time-control study. Clin Pharmacol Ther. 2012;92:72.
61. Gottlieb SS, Kop WJ, Thomas SA, et al. A double-blind placebo-controlled pilot study of controlled-release paroxetine on depression and quality of life in chronic heart failure. Am Heart J. 2007;153:868-873.
62. Hansen BH, Hanash JA, Rasmussen A, et al. Effects of escitalopram in prevention of depression in patients with acute coronary syndrome (DECARD). J Psychosom Res. 2012;72:11-16.
63. Rasmussenr SL, Overo KF, Tanghoj P. Cardiac safety of citalopram: prospective trials and retrospective analyses. J Clin Psychopharmacol. 1999;19:407-415.
64. Pan YJ, KuoKH, Chan HY, McCrone P. Cost-effectivesness and cost-utility of selective serotonin reuptake inhibitors, serotonin norepinephrine reuptake inhibitors, and tricyclic antidepressants in depression with comorbid cardiovascular disease. J Psychiatr Res. 2014;54:70-78.
65. Veith RC, Raskind MA, Caldwell JH, Barnes RF, Gumbrecht G, Ritchie JL. Cardiovascular effects of tricyclic antidepressants in depressed patients with chronic heart disease. N Engl J Med. 1982;306:954-959.
66. Hoc J. The clinical efficacy and side-effects of mianserin and nortriptyline in depressed outpatients: a double-blind randomized trial. Curr Med Res Opin. 1982;8(4):107-115.
67. Roose SP, Glassman AH, Giardina EV. Nortriptyline in depressed patients with left ventricular impairment. JAMA. 1986;256:3253-3257.
68. Dietch JT, Fine M. The effect of nortriptyline in elderly patients with cardiac conduction disease. J Clin Psychiatry. 1987;44:273-275.
69. Glassman AH, Johnson LI, Giardina EV. The use of imipramine in depressed patients with congestive heart failure. JAMA. 1983;250:1997-2001.
70. Raskind M, Veith R, Barnes R, Gumbrecht G. Cardiovascular and antidepressant effects of imipramine in the treatment of secondary depression in patients with ischemic heart disease. Am J Psychiatry. 1982;139:1114-1117.
71. Cohen BE, Panguluri P, Na B, Whooley MA. Psychological risk factors and the metabolic syndrome in patients with coronary heart disease: findings from the Heart and Soul Study. Psychiatry Res. 2010, 175;133-137.
72. Kiev A, Masco HL, Wenger TL, Johnston JA, Batey SR, Holloman LC. The cardiovascular effects of bupropion and nortriptyline in depressed outpatients. Ann Clin Psychiatry. 1994;6(2):107-115.
73. Milani RV, Lavie CJ. Impact of cardiac rehabilitation on depression and its associated mortality. Am J Med. 2007;120:799-806.
74. Ye S, Muntner P, Shimbo D, et al. Behavioral mechanisms, elevated depressive symptoms, and the risk for myocardial infarction or death in individuals with coronary heart disease. J Am Coll Cardiol. 2013;61(6):622-630.
75. Stewart JC, Perkinds A, Callahan CM. Effect of collaborative care for depression on risk of cardiovascular events: Data from the IMPACT randomized controlled trial. Psychosom Med. 2014;76:29-37.
76. Davidson KW, Rieckmann N, Clemow L, et al. Enhanced depression care for patients with acute coronary syndrome and persistent depressive symptoms. Coronary Psychosocial Evaluation Studies Randomized Controlled Trial. Arch Intern Med. 2010;120(7):600-608.
77. Freedland KE, Skala JA, Carney RM, et al. Treatment of depression after coronary artery bypass surgery. Arch Gen Psychiatry. 2009;66(4):387-396.
78. Whang W, Shimbo D, Kronish IM, et al. Depressive symptoms and all-cause mortality in unstable angina pectoris (from the Coronary Psychosocial Evaluation Studies [COPES]. Am J Cardiol. 2010;106(8):1104-1107.
79. Rollman BL, Herbeck, BB. The Bypassing the Blues Trial: Collaborative care for post-CABG depression and implications for future research. Cleve Clin J Med. 2011;78(suppl 1):S4-12.
80. Glozier N, Christensen H, Naismith S, et al. Internet-delivered cognitive behavioral therapy for adults with mild to moderate depression and high cardiovascular disease risks: A randomized attention-controlled trial. PLoS ONE. 2013;8(3):e59139.